Tali Harif, Ph.D, MBA, director, Business Development, UK & Europe at 374Water, shares how pharma manufacturers can adopt responsible waste management, and contribute to a cleaner, safer environment for employees and the community.
Key insights:
- Pharma residues are emitted to the environment via different stages of their lifecycle, from production, to use and disposal - and the waste streams are highly neglected.
- Adopting decentralised waste management technologies, such as SCWO, can sustainably treat contaminated wastewater.
- Six action areas have been defined as national and regional government leaders have collaborated to promote cleaner manufacturing.
On a global scale, the EU is second (after the US) for pharmaceutical sales, holding 25% of the market. Between 2000 and 2020, pharma production doubled in Europe in terms of value, from €127B to €300B respectively, illustrating the industry’s importance as a key asset to the EU economy. That being said, it is recognised that more must be done to manage the multi-faceted detrimental impact the industry has on the environment in the form of environmental pollution and Greenhouse Gas (GHG) emissions.